855.554.5BIO info@biopointinc.com

Case Study

HEOR/Market Access: Interim Executive Oversight & FSP Consulting Support

Contact Us

Client:

A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia.

Key Issues:

As a smaller clinical stage organization, our client lacked a Market Access and HEOR department. As their programs were moving from into clinical development phases, they required high-level strategy to provide input on and contribute to development and implementation of Market Access / HEOR, strategies, and tactics for delivering relevant, actionable, evidence-based HEOR value proposition to support business objectives for clinical development and commercialization.

Solution:

After a thorough needs assessment was completed, BioPoint provided a Market Access expert to provide a gap analysis and an action plan over. Over the course of 12 months the BioPoint consultant acted as interim Market Access VP and helped ensure our client was incorporating the necessary data as early as possible in the product development life cycle to support evidence based
value generation and ultimately successful market access.

Per overall Market Access strategy and internal resource evaluation, over the course of 18 months, BioPoint presented a team of 6 HEOR Project Managers to help execute on various strategic and tactical initiatives, including:

    • Provide guidance on department structure, key competencies, roles/responsibilities, and operational design of an internal HEOR function

    • Conduct targeted literature searches to determine the competitive HEOR landscape, existing HEOR/epidemiologic, and HRQoL data for disease, and published HEOR studies

    • Provide COA/PRO instrument validation and development
    • Develop RFPs, advise on potential HEOR vendors, and oversee selected HEOR vendors

    • Provide ad-hoc support for retrospective claims database analysis, registry analysis, and chart reviews.

Conclusion:

Client was able to implement a robust Market Access strategy and secure the HEOR resources necessary to execute on the strategy leading to successful Payer and HTA interactions. BioPoint’s flexible engagement model allowed our client to better manage business objectives in a flexible cost effective manner as budgets permitted and internal FTE resources were hired.